Bio-Techne (TECH) Income from Continuing Operations (2009 - 2026)
Bio-Techne (TECH) posted quarterly Income from Continuing Operations of 51047000.0 for Q1 2026, up 125.99% year-over-year from 22588000.0 in Q1 2025, and up 34.3% quarter-over-quarter from 38009000.0 in Q4 2025.
Bio-Techne (TECH) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Bio-Techne's Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 51047000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 125.99% year-over-year to 51047000.0; the TTM figure through Mar 2026 stood at 22749000.0 (down 71.78% YoY), while the FY2025 annual figure was 13414000.0, down 111.46% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 51047000.0, up from 38009000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 89734000.0 in Q3 2022, with the low at 104492000.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 49059000.0 (2024), against an average of 37967705.88.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations jumped 615.95% in 2022, then slumped 899.35% in 2025.
- Bio-Techne's Income from Continuing Operations stood at 50005000.0 in 2022, then plunged by 45.08% to 27465000.0 in 2023, then gained by 27.03% to 34890000.0 in 2024, then gained by 8.94% to 38009000.0 in 2025, then soared by 34.3% to 51047000.0 in 2026.
- Business Quant data shows TECH's Income from Continuing Operations at 51047000.0 in Q1 2026, 38009000.0 in Q4 2025, and 38185000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Bio-Techne | 11.33 Bn | 11.12 Bn | 208.29 Mn | 51.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.05 Mn |
| Dec 31, 2025 | 38.01 Mn |
| Sep 30, 2025 | 38.19 Mn |
| Jun 30, 2025 | -104.49 Mn |
| Mar 31, 2025 | 22.59 Mn |
| Dec 31, 2024 | 34.89 Mn |
| Sep 30, 2024 | 33.60 Mn |
| Jun 30, 2024 | -10.46 Mn |
| Mar 31, 2024 | 49.06 Mn |
| Dec 31, 2023 | 27.47 Mn |
| Sep 30, 2023 | 50.99 Mn |
| Jun 30, 2023 | 75.48 Mn |
| Mar 31, 2023 | 70.22 Mn |
| Dec 31, 2022 | 50.01 Mn |
| Sep 30, 2022 | 89.73 Mn |
| Jun 30, 2022 | 68.98 Mn |
| Mar 31, 2022 | 60.14 Mn |
| Dec 31, 2021 | 72.06 Mn |
| Sep 30, 2021 | 68.98 Mn |
| Jun 30, 2021 | -13.37 Mn |